Journal
CURRENT DIABETES REPORTS
Volume 13, Issue 4, Pages 560-566Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-013-0385-9
Keywords
TNF-alpha; TNF receptor1(TNFR1); TNF receptor 2 (TNFR2); Inflammation; Biomarker; Chronic kidney disease (CKD); Diabetes; Diabetic nephropathy
Categories
Ask authors/readers for more resources
Despite 2 decades of advances in therapy of diabetic patients, the prevalence of diabetic nephropathy among patients with diabetes has not decreased. However, large-scale multicenter studies have achieved great success in terms of the reduction of albuminuria, suggesting that albuminuria might not be an accurate surrogate marker for slowing the rate of renal function decline. It is important to be able to identify individuals at high risk for renal function decline, or ultimately, end-stage kidney disease (ESKD) and its associated cardiovascular disease (CVD). More sensitive early biomarkers, other than albuminuria and the estimated glomerular filtration rate (eGFR), should be required. Recently, serum concentrations of soluble tumor necrosis factor (TNF), receptor 1 (TNFR1), and TNFR2 have predicted future GFR loss and ESKD in patients of a wide variety of stages and both types of diabetes. Longitudinal interventional studies are needed to validate these biomarkers in a broad range of populations prior to implementation in routine diabetes management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available